NKCFO LLC’s Vanda Pharmaceuticals VNDA Stock Holding History

NKCFO LLC’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-12,000	Closed	-$180K	–	166
2021 Q1	$180K	Buy	+12,000	New	+$194K	0.07%	86

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

NKCFO LLC's VNDA Position: Q2 2021 in Review

NKCFO LLC sold out of Vanda Pharmaceuticals (VNDA) in Q2 2021, closing a stake of 12,000 shares — an estimated $180K sold.

NKCFO LLC first reported a position in VNDA in Q1 2021 and held it in 1 quarter. The position peaked at $180K in Q1 2021. 181 funds tracked by Wall St. Rank hold VNDA as of Q2 2021.

NKCFO LLC reported no remaining Vanda Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
NKCFO LLC sold 12,000 Vanda Pharmaceuticals shares in Q2 2021, an estimated $180K.
NKCFO LLC first reported a position in Vanda Pharmaceuticals in Q1 2021 and held it in 1 quarter.
NKCFO LLC's Vanda Pharmaceuticals position peaked at $180K in Q1 2021.
181 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2021.

Based on NKCFO LLC's 13F filing for Q2 2021, filed 22 Jul 2021.